Medtronic Q4 Earnings Preview: Can $9.61B Revenue Test Reverse Its Low-Growth Valuation Discount?

MedtronicTo release its financial report on June 3, 2026; Wall Street expects its fourth-quarter revenue to be $9.61 billion, with earnings per share of $1.55.

The bullish case is that loose expectations give Medtronic room to deliver strong results, with net profit exceeding Wall Street estimates for the past four quarters. The bearish case is that as fiscal 2026 comes to an end, even if management performs well this quarter, a guidance for 2027 near the lower end would mean slowing earnings-per-share growth, which would limit multiple expansion. The key on June 3 is whether Medtronic can meet expectations and boost investor confidence in its next phase of growth.

The cardiovascular business portfolio grew 11% year-over-year in the previous quarter, with cardiac ablation solutions revenue surging 80% and diabetes business revenue increasing by 8.3%. The business portfolio mix is more significant than aggregate figures, as high-growth sub-portfolios warrant higher valuations. Investors should focus on whether management can demonstrate the sustainability of portfolio improvements and confirm that growth in 2027 will be driven by high-value segments.

The positive scenario is that management describes 2027 as a period of improved business portfolio, linking growth to the momentum in its cardiovascular business, with dividend support also being important; if management maintains its full-year outlook unchanged, Medtronic may remain a defensive healthcare stock. The main risk is disappointing commentary on 2027, which could lead to a low-growth valuation discount for the stock, but currently the situation is more balanced, with investors focusing more on execution.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; please refer to actual announcements for authoritative information. If you have any questions, please contact: biz@staff.sina.com.cn.

Executive Editor: Xiaolang Express